Protocol Ledger

NCT03683251 · Phase III · RECRUITING

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Interventional Phase III clinical trial protocol NCT03683251 sponsored by Roche / Genentech in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-20 Enrollment: 1,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03683251
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03683251
Protocol FieldVerified Registry Value
NCT IdentifierNCT03683251
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,000 participants (ESTIMATED)
Registered Start Date2018-09-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03683251
Hospital Research SiteLocationSite Profile
California Retina ConsultantsBakersfield, CAOpen Hospital Dossier ->
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->
The Retina PartnersEncino, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI